MAM
HQL

Meeder Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

Meeder Asset Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,840
Closed -$39K – 2543
2021
Q2 		$39K Buy
+1,840
New +$37.1K ﹤0.01% 1213

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Meeder Asset Management's HQL Position: Q3 2021 in Review

Meeder Asset Management sold out of abrdn Life Sciences Investors (HQL) in Q3 2021, closing a stake of 1,840 shares — an estimated $39K sold.

Meeder Asset Management first reported a position in HQL in Q2 2021 and held it in 1 quarter. The position peaked at $39K in Q2 2021. 67 funds tracked by Wall St. Rank hold HQL as of Q3 2021.

  • Meeder Asset Management reported no remaining abrdn Life Sciences Investors position as of Q3 2021 after selling out during the quarter.
  • Meeder Asset Management sold 1,840 abrdn Life Sciences Investors shares in Q3 2021, an estimated $39K.
  • Meeder Asset Management first reported a position in abrdn Life Sciences Investors in Q2 2021 and held it in 1 quarter.
  • Meeder Asset Management's abrdn Life Sciences Investors position peaked at $39K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.